Rapid Whole-Genome Sequencing as a First-Line Test Is Likely to Significantly Reduce the Cost of Acute Care in a Private Payer System
The Journal of Applied Laboratory Medicine · 2025
DOI: 10.1093/jalm/jfaf045 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Applied Laboratory Medicine, 2025. Verfasst von Christy Moore und 8 weiteren Autor:innen. Beteiligte Einrichtung: Health Trend Solutions, Blue Shield of California, Oakland, CA, United States. Hauptthemen laut MEDLINE: Whole Genome Sequencing, Health Care Costs, Genetic Testing, Genetic Diseases, Inborn. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Blue Shield of California, Rady Children's Institute for Genomic Medicine.
Abstract (Originalsprache)
Background
Genetic disorders are a leading contributor to morbidity and mortality in neonatal and pediatric intensive care units. Rapid whole-genome sequencing (rWGS) has demonstrated improved clinical outcomes and reduced costs of care. The objective of this study was to predict the effect of rWGS on healthcare spending if implemented as a first-line diagnostic test in the Blue Shield of California (BSC) private payer system.
Methods
This study applied private payer reimbursement methods and rates to clinical outcomes of rWGS on pediatric inpatient care as determined by a previous study of publicly insured infants in Project Baby Bear. BSC patients who were clinically similar to the Project Baby Bear cohort were identified by matching on diagnosis-related group and severity of illness. Payment data from these BSC patients was used to estimate the financial impact of clinical outcomes resulting from rWGS testing in a commercially insured pediatric population.
Results
The analysis estimated a reduction of $5.8 million to $7.8 million in inpatient payments due to an estimated 457 to 592 avoided inpatient days due to rWGS results. With an estimated cost of sequencing at $2.7 million for the entire cohort (n = 184), the financial impact of rWGS as a first-tier test in the intensive care unit resulted in estimated net savings to BSC of $16 730 to $28 061 per patient sequenced.
Conclusions
Implementation of rWGS using the protocols established in Project Baby Bear is likely to result in significant reductions in healthcare spending among privately insured patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Health Trend Solutions, Blue Shield of California, Oakland, CA, United States.
- Rady Children's Institute for Genomic Medicine, San Diego, CA, United States.
ORCID-Profile: Christy Moore, Madison Arenchild, Stephen F Kingsmore, Justin Field, Russell Nofsinger
Förderung
- Blue Shield of California
- Rady Children's Institute for Genomic Medicine
Zitieren
APA
Moore, C., Arenchild, M., Waldman, B., Rego, S., Kingsmore, S. F., Field, J., Barnhart, J., Nee, S., & Nofsinger, R. (2025). Rapid Whole-Genome Sequencing as a First-Line Test Is Likely to Significantly Reduce the Cost of Acute Care in a Private Payer System. The Journal of Applied Laboratory Medicine. https://doi.org/10.1093/jalm/jfaf045
Vancouver
Moore C, Arenchild M, Waldman B, Rego S, Kingsmore SF, Field J, et al. Rapid Whole-Genome Sequencing as a First-Line Test Is Likely to Significantly Reduce the Cost of Acute Care in a Private Payer System. The Journal of Applied Laboratory Medicine. 2025. doi:10.1093/jalm/jfaf045
BibTeX
@article{Moore2025,
author = {Moore, Christy and Arenchild, Madison and Waldman, Bryce and Rego, Seema and Kingsmore, Stephen F and Field, Justin and Barnhart, Jason and Nee, Stephanie and Nofsinger, Russell},
title = {Rapid Whole-Genome Sequencing as a First-Line Test Is Likely to Significantly Reduce the Cost of Acute Care in a Private Payer System},
journal = {The Journal of Applied Laboratory Medicine},
year = {2025},
doi = {10.1093/jalm/jfaf045}
}
EUVIMED